Zewei Wang

564 total citations
27 papers, 420 citations indexed

About

Zewei Wang is a scholar working on Surgery, Oncology and Immunology. According to data from OpenAlex, Zewei Wang has authored 27 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Surgery, 19 papers in Oncology and 12 papers in Immunology. Recurrent topics in Zewei Wang's work include Bladder and Urothelial Cancer Treatments (19 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Renal cell carcinoma treatment (8 papers). Zewei Wang is often cited by papers focused on Bladder and Urothelial Cancer Treatments (19 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Renal cell carcinoma treatment (8 papers). Zewei Wang collaborates with scholars based in China. Zewei Wang's co-authors include Jiejie Xu, Yu Zhu, Le Xu, Hangcheng Fu, Han Zeng, Zhaopei Liu, Yuan Chang, Kaifeng Jin, Huyang Xie and Bo Dai and has published in prestigious journals such as Clinical Cancer Research, British Journal of Cancer and The Journal of Pathology.

In The Last Decade

Zewei Wang

25 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zewei Wang China 13 206 199 148 131 106 27 420
De Sen Wan China 9 247 1.2× 150 0.8× 119 0.8× 65 0.5× 85 0.8× 35 416
Nathan Tonlaar United States 6 179 0.9× 154 0.8× 117 0.8× 84 0.6× 125 1.2× 13 414
Yiyi Xi China 8 136 0.7× 76 0.4× 186 1.3× 82 0.6× 66 0.6× 9 315
Astrid De Meulenaere Belgium 10 261 1.3× 107 0.5× 49 0.3× 65 0.5× 75 0.7× 16 329
Zul Fazreen Singapore 6 282 1.4× 167 0.8× 72 0.5× 40 0.3× 122 1.2× 8 391
Dongming Zhu China 10 202 1.0× 129 0.6× 113 0.8× 46 0.4× 42 0.4× 21 330
Teming Zhang China 6 160 0.8× 110 0.6× 135 0.9× 25 0.2× 114 1.1× 10 324
Mohamed Abu Nada Qatar 10 281 1.4× 254 1.3× 137 0.9× 28 0.2× 68 0.6× 23 447
Xiaofang Xing China 9 191 0.9× 101 0.5× 188 1.3× 42 0.3× 102 1.0× 15 386
Fumiaki Shiratori Japan 10 98 0.5× 56 0.3× 79 0.5× 62 0.5× 56 0.5× 35 223

Countries citing papers authored by Zewei Wang

Since Specialization
Citations

This map shows the geographic impact of Zewei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zewei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zewei Wang more than expected).

Fields of papers citing papers by Zewei Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zewei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zewei Wang. The network helps show where Zewei Wang may publish in the future.

Co-authorship network of co-authors of Zewei Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Zewei Wang. A scholar is included among the top collaborators of Zewei Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zewei Wang. Zewei Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Zhaopei, Kaifeng Jin, Han Zeng, et al.. (2025). ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma. Clinical Cancer Research. 31(20). 4311–4322. 1 indexed citations
2.
Jin, Kaifeng, Zhaopei Liu, Han Zeng, et al.. (2025). Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression. Journal for ImmunoTherapy of Cancer. 13(1). e010964–e010964. 1 indexed citations
3.
4.
Jin, Kaifeng, Ziyue Xu, Bingyu Li, et al.. (2024). TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma. The Journal of Pathology. 263(2). 139–149. 4 indexed citations
5.
Liu, Ge, Kaifeng Jin, Zhaopei Liu, et al.. (2024). Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer. Cancer Science. 115(4). 1306–1316. 3 indexed citations
6.
Jin, Shengming, Han Zeng, Zhaopei Liu, et al.. (2022). Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. Annals of Surgical Oncology. 29(4). 2495–2503. 4 indexed citations
7.
Liu, Zhaopei, Han Zeng, Kaifeng Jin, et al.. (2022). TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. British Journal of Cancer. 126(9). 1310–1317. 14 indexed citations
8.
Zeng, Han, Kaifeng Jin, Zhaopei Liu, et al.. (2022). Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. Cancer Immunology Immunotherapy. 71(9). 2117–2126. 2 indexed citations
9.
Liu, Zhaopei, Kaifeng Jin, Han Zeng, et al.. (2022). Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients. British Journal of Cancer. 127(9). 1718–1725. 2 indexed citations
10.
Jin, Kaifeng, Han Zeng, Zhaopei Liu, et al.. (2022). CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. British Journal of Cancer. 126(11). 1581–1588. 28 indexed citations
11.
Yan, Sen, Han Zeng, Kaifeng Jin, et al.. (2022). NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. Journal for ImmunoTherapy of Cancer. 10(5). e004569–e004569. 12 indexed citations
12.
Xu, Yijia, Han Zeng, Kaifeng Jin, et al.. (2022). Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. Journal for ImmunoTherapy of Cancer. 10(3). e003416–e003416. 71 indexed citations
13.
Sun, Mengmeng, Han Zeng, Kaifeng Jin, et al.. (2021). Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. Cancer Immunology Immunotherapy. 71(6). 1497–1506. 25 indexed citations
14.
Wang, Zewei, Quan Zhou, Han Zeng, et al.. (2020). Tumor-infiltrating IL-17A + cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer. OncoImmunology. 9(1). 1747332–1747332. 11 indexed citations
15.
Zhou, Quan, Zewei Wang, Han Zeng, et al.. (2020). Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin + cell abundance. OncoImmunology. 9(1). 1747333–1747333. 15 indexed citations
16.
Liu, Yidong, Qiang Fu, Zewei Wang, et al.. (2017). Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 35(6). 349–355. 22 indexed citations
17.
Wang, Zewei, Huyang Xie, Lin Zhou, et al.. (2016). CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget. 7(32). 51525–51534. 37 indexed citations
18.
Fu, Hangcheng, Yu Zhu, Yiwei Wang, et al.. (2016). Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma. Annals of Surgical Oncology. 24(5). 1435–1442. 35 indexed citations
19.
Wang, Zewei, Le Xu, Yuan Chang, et al.. (2016). IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma. Tumor Biology. 37(8). 11127–11134. 13 indexed citations
20.
Liu, Yidong, Yuan Zhang, Qiang Fu, et al.. (2016). Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma. Oncotarget. 7(31). 50017–50026. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by De Sen Wan Breakdown of academic impact, for papers by Nathan Tonlaar Breakdown of academic impact, for papers by Yiyi Xi Breakdown of academic impact, for papers by Astrid De Meulenaere Breakdown of academic impact, for papers by Zul Fazreen Breakdown of academic impact, for papers by Dongming Zhu Breakdown of academic impact, for papers by Teming Zhang Breakdown of academic impact, for papers by Mohamed Abu Nada Breakdown of academic impact, for papers by Xiaofang Xing Breakdown of academic impact, for papers by Fumiaki Shiratori
Rankless by CCL
2026